Can-Fite BioPharma (CANF) News Today → Gold Mania (From Stansberry Research) (Ad) Free CANF Stock Alerts $2.09 +0.06 (+2.96%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCan-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.comamericanbankingnews.com - April 30 at 2:30 AMLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journalbusinesswire.com - April 25 at 7:00 AMCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASHbusinesswire.com - April 15 at 7:00 AMCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patientsbusinesswire.com - April 3 at 7:00 AMCan-Fite BioPharma Ltd.: Can-Fite Reports 2023 Financial Results and Clinical Updatefinanznachrichten.de - March 28 at 7:50 AMNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conferencebusinesswire.com - March 11 at 7:00 AMCan-Fite secures Canadian patent for liver disease druginvesting.com - March 1 at 8:37 AMCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canadabusinesswire.com - February 28 at 7:00 AMHistorical Priceswsj.com - February 24 at 6:51 PMCan-Fite BioPharma Ltd. (CANF)finance.yahoo.com - February 22 at 11:24 PMBuy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical Prospectsmarkets.businessinsider.com - February 8 at 12:01 AMCan Fite Biopharma Ltd (CANF)investing.com - January 30 at 8:26 AMCan Fite Biopharma Ltd ADR (CANF)investing.com - January 30 at 8:26 AMCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indicationfinance.yahoo.com - January 30 at 8:26 AMCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Studyfinance.yahoo.com - January 29 at 8:40 AMThe Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studiesfinance.yahoo.com - December 20 at 7:35 AMCan-Fite Reports FDA Positive Response To Its Psoriasis Pediatric Plan - Quick Factsmarkets.businessinsider.com - December 18 at 8:27 AMCan-Fite Received FDA Positive Response to Psoriasis Pediatric Planfinance.yahoo.com - December 18 at 7:12 AMCan-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Developmentfinance.yahoo.com - December 4 at 7:53 AMCan-Fite Reports Third Quarter 2023 Financial Results and Clinical Updatefinance.yahoo.com - November 30 at 7:25 AMWhy Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?msn.com - November 21 at 2:44 PMCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceedsfinance.yahoo.com - November 21 at 2:44 PMCan-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenosonfinance.yahoo.com - November 21 at 9:43 AMCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Trackfinance.yahoo.com - November 1 at 7:20 AMCan-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowfinance.yahoo.com - October 30 at 1:03 PMCan Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Actionfinance.yahoo.com - October 30 at 8:03 AMCan-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugsfinance.yahoo.com - October 26 at 7:36 AMCan-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companiesfinance.yahoo.com - October 9 at 7:35 AMCan-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)finance.yahoo.com - September 27 at 7:33 AMCan-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conferencefinance.yahoo.com - September 7 at 8:14 AMCan-Fite Biopharma discloses $100M mixed shelf offering - filingseekingalpha.com - September 1 at 5:57 PMCan-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studiesfinance.yahoo.com - August 31 at 7:15 AMCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating ...businesswire.com - August 24 at 2:30 PMCan-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndromefinance.yahoo.com - August 24 at 7:31 AMCan-Fite Submits Pediatric Study Plan To Allow Registration Of Piclidenosonmarkets.businessinsider.com - August 18 at 8:19 AMCan-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasisfinance.yahoo.com - August 18 at 7:36 AMCan-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundationfinance.yahoo.com - July 17 at 7:52 AMPresenting on the Emerging Growth Conference on July 12 & 13 Register Nowfinance.yahoo.com - July 11 at 7:32 AMCan-Fite to Present at the Emerging Growth Conference on July 13, 2023finance.yahoo.com - July 7 at 8:28 AMCan-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Planfinance.yahoo.com - June 29 at 7:43 AMCan-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Datathestreet.com - June 27 at 9:38 AMCANF Rises on IND Submission Plans in Pancreatic Cancermsn.com - June 13 at 1:39 PMCan-Fite To Seek FDA Clearance For Phase II Trial Of Namodenoson In Pancreatic Cancermarkets.businessinsider.com - June 13 at 8:55 AMCan-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenosonfinance.yahoo.com - June 13 at 8:55 AMCan-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Bostonfinance.yahoo.com - June 2 at 7:31 AMCan-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Updatefinance.yahoo.com - June 1 at 7:38 AMCan-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)finance.yahoo.com - May 30 at 8:01 AMCan-Fite: Presenting Namodenoson's New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023benzinga.com - May 15 at 8:05 AMCan-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023finance.yahoo.com - May 15 at 8:05 AMPre-market Movers: GFAI, SONO, KLXE, CDNA, DMRC…markets.businessinsider.com - May 11 at 7:46 AM Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Mania (Ad)Former Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite). See his free reveal right here. CANF Media Mentions By Week CANF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CANF News Sentiment▼0.000.42▲Average Medical News Sentiment CANF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CANF Articles This Week▼11▲CANF Articles Average Week Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Pulmatrix News Enveric Biosciences News Pasithea Therapeutics News Shuttle Pharmaceuticals News ASLAN Pharmaceuticals News Adial Pharmaceuticals News Vaccinex News Tenax Therapeutics News Trevena News Kineta News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CANF) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
